Chief Scientific Officer-Emeritus, GeoVax Labs, Inc.
Harriet Latham Robinson founded GeoVax Labs, Inc. and GeoVax, Inc. Presently, she holds the position of Chief Scientific Officer-Emeritus at GeoVax Labs, Inc.
Dr. Robinson previously was Professor at University of Massachusetts Medical Center, Member of American Society for Microbiology, Member of National Institutes of Health, Member of World Health Organization, Member of Bill & Melinda Gates Foundation Trust, Professor at Emory University, Member of The Rockefeller Foundation, Member of National Foundation for Infectious Diseases and Member of American Academy of Sciences.
She received an undergraduate degree from Swarthmore College and a graduate degree and a doctorate from Massachusetts Institute of Technology.
https://www.wsj.com/market-data/quotes/GOVXW/company-people/executive-profile/15427890
DetailSource
Name : Harriet L Robinson / [H L Robinson]
Birth Date : Feb 1938
Residence Date : 2010-2020
Address : 620 Sand Hill Rd Apt 124d / Palo Alto, California, USA / 94304
Second Residence Date : 2016
Second Address : 1642 Mason Mill Rd Ne / Atlanta, Georgia, USA / 30329
Third Residence Date : 1983-1999
Third Address : 3 Birchwood Dr / Southborough, Massachusetts, USA / 01772
Fourth Residence Date : 1990-1997
Fourth Address : 30 Birchwood Dr Southborough, Massachusetts, USA / 01772
Born Feb 10, 1938
https://vaccines.emory.edu/faculty-evc/affiliate/robinson_harriet.html
2021-12-16-emory-edu-vaccines-faculty-robinson-harriet.pdf
2021-12-16-emory-edu-vaccines-faculty-robinson-harriet-img-1.jpg
Affiliate Faculty
Emory Vaccine Center
Chief Scientific Officer
GeoVax, Inc
Emeritus Professor of Microbiology and Immunology
Emory University School of Medicine
Phone: 678-384-7223
Fax: 678-384-7281
Email: Email: hrobinson@geovax.com
Dr. Robinson has a multi-protein clade B DNA/MVA vaccine regimen in clinical trials through the US HIV vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's laboratory at the US NIH.
https://www.linkedin.com/in/harriet-l-robinson-b3b745a
2021-12-16-linkedin-com-harriet-l-robinson-b3b745a.pdf
https://drive.google.com/file/d/1W5yw5TCBpIF6N_sc1GtaAyAvm9jpkGse/view?usp=sharing
2021-12-16-linkedin-com-harriet-l-robinson-b3b745a-img-1.jpg
https://drive.google.com/file/d/1HjliJajzzNmAPjLc5L8qKipE3hKrdFSH/view?usp=sharing
GeoVax Labs, Inc.
Massachusetts Institute of Technology
Harriet L. Robinson leads the HIV vaccine program at GeoVax, Inc., a biotech company she co-founded to facilitate taking the vaccine from the research laboratory to clinical use. The HIV vaccine uses a single DNA prime and modified vaccinia Ankara (MVA) boost to express virus-like particles displaying trimeric, fusion-competent Env. The vaccine addresses the clade B epidemic in the Americas, Europe, and Japan, and has been tested in trials involving 500 humans, where it has had an outstanding safety record and reproducible immunogenicity.
The Enemy of My Enemy is My Friend: Viral Version https://lnkd.in/dQuPm5U
Liked by Harriet L. Robinson
Director HIV Vaccines
2016 - Present5 years
USA
Chief Scientific Officer
2010 - 20166 years
Smryna, GA
Senior Vice President, Research and Development
2008 - 20102 years
Smyrna, GA
Scientific Advisor
2001 - 20087 years
Co-Founder
2001 - 2001less than a year
Asa Griggs Candler Professor of Microbiology and Immunology
Emory University
1999 - 20089 years
Atlanta, GA
Chief, Division of Microbiology and Immunology
1997 - 200811 years
Atlanta, GA
Professor, Department of Microbiology and Immunology
1997 - 200811 years
Atlanta, GA
Professor, Department of Pathology
University of Massachusetts Medical Center
1988 - 19979 years
Worcester, MA
Worcester Foundation for Experimental Biology
10 years
Co-Director, Cancer Center
1986 - 19871 year
Staff, then Senior, then Principal Science
1977 - 198710 years
Family Years at Home
Home
1967 - 197710 years
National Science Foundation Fellow
University of California, Berkeley; Laboratory of Dr. Harry Rubin
1965 - 19672 years
Berkeley, CA
Candidate for a Doctoral Degree
MIT; Dr. James E. Darnell, Thesis Advisor
1963 - 19652 years
Cambridge, MA
Massachusetts Institute of Technology
Ph.D.
1962 - 1965
Massachusetts Institute of Technology
M.S.
1959 - 1961
Swarthmore College
B.A.
1955 - 1959
Girls’ Latin School
-
1951 - 1955
A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
Sci Rep. 2018 Jan 16;8(1):864. doi: 10.1038/s41598-017-19041-y January 16, 2018
Other authors
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
J Virol. 2017 Nov 30;91(24). pii: e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15 November 30, 2017
Other authors
A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model
Sci Rep. 2017 Nov 7;7(1):14769. doi: 10.1038/s41598-017-15039-8 November 7, 2017
Other authors
HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site
PLoS One 2017 Oct 11;12(10):e0177863. doi: 10.1371/journal.pone.0177863. eCollection 2017 October 11, 2017
Other authors
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
PLoS One Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017 July 20, 2017
A phase 1 trial of a clade B HIV vaccine in HIV-uninfected adults evaluated the safety and immunogenicity of a DNA prime co-expressing GM-CSF (Dg) followed by different numbers and intervals of modified vaccinia Ankara Boosts (M). Both vaccines produce virus-like particles presenting membrane-bound Env.
Other authors
Local control of rectal challenges in DNA/MVA vaccinated macaques protected against a 1st series of SIV challenges
Journal of Virology; 88(10): 5864-5869 Feb 2014
Other authors
Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles
Journal of Infectious Diseases; 210:99-110 Jan 2014
Other authors
Non-neutralizing antibodies in prevention of HIV infection
Opinion on Biological Therapy; 13(2): 197-207 Feb 2013
See publication
Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Journal of Infectious Diseases; 203(5); 610-619 2011
Other authors
HIV-1 DNA/MVA Vaccination Reduces the Per Exposure Probability of Infection during Repeated Mucosal SHIV Challenges
Virology; 352:216-25 Aug 2006
Other authors
DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
AIDS Res Hum Retroviruses; 20:1335-47 Dec 2004
Other authors
Editorial Appointments
-
2015
2006 - current Journal of Infectious Diseases, Editorial Board
2006 - current Journal of Virology, Editorial Board
2006 - 2011 Clinical and Vaccine Immunology, Editorial Board
1993 – 2001 Virology, Section Editor
1986 – 1993 Virology, Editorial Board
1983 – 1992 Journal of Virology, Editorial Board
Groundbreakers Award
Atlanta Magazine, Atlanta, GA
2012
Distinguished Faculty Member
Emory University Emeritus College, Atlanta, GA
2011
Georgia Bio Community Award
Georgia Bio, Atlanta, GA
2011
Member-at-Large, Medical Sciences Section
Fellow Association for the Advancement of Science
2010
Fellow, American Association for the Advancement of Science
-
2008
Dean's Distinguished Faculty Lecturer and Award
Emory University School of Medicine
2007
The Mary Lynn Morgan Annual Lectureship on Women in the Health Professions
Center for Women at Emory University
2006
Member of Electorate Nominating Committee
AAAS - American Association for the Advancement of Science
2005
Atlanta Business Chronicle Healthcare Hero
Atlanta Business Chronicle, Atlanta, GA
2003
Albert E. Levy Scientific Research Award
Emory University
2002
Fellow & Member, Board of Governors
American Academy of Microbiology
2002
Most cited paper in Immunology
Science
2002
November/December; Science 292:69:74
American Association of Immunologists
-
American Society of Microbiology
-
American Society of Virology
-